Editas Medicine
EDIT • NASDAQ
Editas Medicine is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Gilmore O'Neill, with a market cap of $218.3M.
CEOGilmore O'Neill
Next Earnings
Upcoming earnings announcement for Editas Medicine
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.30
Revenue Estimate
$5.9M
Earnings History
Past 12 earnings reports for Editas Medicine
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Q4 2025 | -$0.06Est: -$0.24 | +75.0% | $24.7MEst: $7.9M | +214.6% |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.28Est: -$0.38 | +26.3% | $7.5MEst: $3.6M | +108.7% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.63Est: -$0.39 | -61.5% | $3.6MEst: $1.4M | +151.5% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.43Est: -$0.59 | +27.1% | $4.7MEst: $706.1K | +559.7% | 10-Q |
| Mar 5, 2025 | Q4 2024 | -$0.40Est: -$0.38 | -5.3% | $30.6MEst: $32.2M | -5.0% | 10-K |
| Nov 4, 2024 | Q3 2024 | -$0.75Est: -$0.78 | +3.8% | $61.0KEst: $2.7M | -97.7% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.82Est: -$0.70 | -17.1% | $513.0KEst: $5.1M | -89.9% | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.76Est: -$0.67 | -13.4% | $1.1MEst: $7.9M | -85.6% | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.23Est: -$0.54 | +57.4% | $60.1MEst: $7.9M | +656.3% | 10-K |
| Nov 3, 2023 | Q3 2023 | -$0.55Est: -$0.57 | +3.5% | $5.3MEst: $3.4M | +56.0% | — |
| Aug 2, 2023 | Q2 2023 | -$0.56Est: -$0.76 | +26.3% | $2.9MEst: $6.3M | -54.0% | 10-Q |
| May 5, 2023 | Q1 2023 | -$0.71Est: -$0.78 | +9.0% | $9.9MEst: $3.0M | +227.3% | — |